近日,来自恒瑞源正的研发团队在Nature Communications杂志(影响影子16.6)上发表题为HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice的研究论文。详细介绍了公司首个进入临床阶段的TCR-T产品(HRYZ-T101)的研发过程、作用机制和临床前药效毒理等研究结果。HRYZ-T101为全球首创新药(First in class),属于国内外均未上市的新靶点,新结构,新机制创新药。
参考文献:Long, J. et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice. Nature Communications 15, 2271 (2024).